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Abstract: The initial observations linking vitamin D to type 2 diabetes in humans came 
from studies showing that both healthy and diabetic subjects had a seasonal variation of 
glycemic control. Currently, there is evidence supporting that vitamin D status is important 
to regulate some pathways related to type 2 diabetes development. Since the activation of 
inflammatory pathways interferes with normal metabolism and disrupts proper insulin 
signaling, it is hypothesized that vitamin D could influence glucose homeostasis by 
modulating inflammatory response. Human studies investigating the impact of vitamin D 
supplementation on inflammatory biomarkers of subjects with or at high risk of developing 
type 2 diabetes are scarce and have generated conflicting results. Based on available 
clinical and epidemiological data, the positive effects of vitamin D seem to be primarily 
related to its action on insulin secretion and sensitivity and secondary to its action on 
inflammation. Future studies specifically designed to investigate the role of vitamin D on 
type 2 diabetes using inflammation as the main outcome are urgently needed in order to 
provide a more robust link between vitamin D, inflammation and type 2 diabetes.  
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1. Introduction 
Type 2 diabetes is one of the main noncommunicable chronic diseases and its complications have 
become a major cause of morbidity and mortality worldwide. It has been estimated that 285 million 
individuals have diabetes, most of them type 2 diabetes [1]. Vitamin D deficiency is also considered a 
public health problem around the world. In 2008, it was estimated that 1 billion individuals presented 
vitamin D insufficiency or deficiency [2]. 
Much evidence suggested that vitamin D is involved in several mechanisms in addition to bone 
metabolism [3] and its role in abnormal glucose metabolism as well as in type 2 diabetes has been 
demonstrated [4,5]. A recent review indicates that vitamin D deficiency may predispose to glucose 
intolerance, altered insulin secretion and type 2 diabetes [6], either through a direct action via vitamin 
D receptor (VDR) activation or indirectly via calcemic hormones and also via inflammation [7].  
Furthermore, in observational studies the risk of diabetes was negatively associated with increased 
vitamin D concentrations [6,8]. In fact, Mitri et al. [9], in a systematic review, confirmed such 
evidence by evaluating vitamin D intake and 25-hydroxyvitamin D (25OHD) levels. In 8 observational 
studies, vitamin D intake >500 international units (IU)/day decreased the risk of type 2 diabetes by 
13% compared with vitamin D intake <200 IU/day.  Individuals with the highest 25OHD status   
(>25 ng/mL) had a 43% lower risk of developing type 2 diabetes (95% confidence interval 24–57%) 
compared with those in the lowest group (<14 ng/mL).  
On the other hand, information pooled from vitamin D intervention trials lack conclusive evidence. 
In the same systematic review [9], no effect of vitamin D supplementation on glycemic outcomes were 
demonstrated in post hoc analysis from eleven trials. However, it has been observed some potential 
benefits of vitamin D supplementation in non-diabetics [10]. There are several potential reasons for the 
conflicting findings from human studies of vitamin D and diabetes, which are discussed in the 
present review. 
Inflammation participates in host defenses against infectious agents and injury, but it also 
contributes to the pathophysiology of many chronic diseases. There is evidence for a direct link 
between type 2 diabetes and subclinical inflammation, which supports the concept that such disease is, 
at least in part, an inflammatory condition [11]. Moreover, it has been observed that the relationship 
between vitamin D and low-intensity chronic inflammation and insulin resistance in type 2 diabetes 
can be mediated in part by the immune-modulating properties of the 1,25(OH)2D3, which is able to 
downregulate the production of pro-inflammatory cytokines [12]. 
Considering that inflammatory status as well vitamin D insufficiency create an environment 
conducive to the development and progression of several diseases, the present review will focus on the 
associations observed between vitamin D status and its potential immune-modulating effects in the 
metabolism of type 2 diabetes biomarkers.  
2. Inflammation, Insulin Resistance and Type 2 Diabetes 
Chronic low-grade inflammation, frequently observed in obese individuals, is involved in the 
development of insulin resistance, which increases the risk of type 2 diabetes. The first link between 
obesity, inflammation and insulin action came from a study developed by Hotamisligil et al. [13], 
which demonstrated that tumor necrosis factor (TNF)-α mRNA expression in the adipose tissue of Nutrients 2012, 4  54 
 
obese animal (fa/fa rat and ob/ob mouse) was increased and that the neutralization of TNF-α improved 
insulin action on glucose uptake. It is now acknowledged that not only TNF-α but an array of 
inflammatory cytokines are elevated in obese tissues, including interleukin (IL)-1β, IL-6, monocyte 
chemoattractant protein (MCP)-1, and others [14]. A major finding advancing in the understanding of 
obesity-induced inflammation was the discovery that immune cells, in particular adipose tissue infiltrated 
macrophages, largely contribute to the increased production of inflammatory mediators [15,16]. 
There is strong evidence that activation of inflammatory pathways interferes with normal 
metabolism and disrupts proper insulin signalling [17]. Briefly, insulin binding to its receptor triggers 
tyrosine phosphorylation of insulin receptor substrates (IRS), leading to activation of phosphatidylinositol 
3-kinase (PI3K)-Akt pathway, which is responsible for insulin action on glucose uptake and suppression 
of gluconeogenesis [18]. In response to inflammatory signals, c-jun N-terminal kinase (JNK) and 
inhibitor of κB kinase (IKK) are activated and can target IRS-1 for serine phosphorylation, which 
inhibits the insulin receptor signalling cascade. Not only JNK and IKK, but also other kinases, such  
as protein kinase C (PKC)-θ, can inhibit IRS-1 through serine phosphorylation, implying that 
activation of diverse cellular networks can antagonize insulin signalling. Apart from inhibiting insulin  
action through targeting insulin signalling molecules, JNK and IKK can also regulate downstream 
transcriptional programs through the transcription factors activator protein (AP)-1 and nuclear factor 
(NF)-κB, respectively, resulting in increased expression of proinflammatory cytokines, such as IL-1β 
and TNF-α [17,19,20]. These cytokines can target cell membrane receptors, feeding into inflammatory 
response and exacerbating insulin resistance. Another important molecular mediator that link 
proinflammatory cytokine to inhibition of insulin signalling are suppressors of cytokine signalling 
(SOCS) 1 and 3, induced by IL-6, which lead to ubiquitinylation and degradation of IRS proteins [21].  
Insulin resistance can also be triggered by the presence of metabolic stressors, such as high blood 
non-esterified fatty acids (NEFA) levels, which compromises insulin sensitivity by reducing the action 
of this hormone in peripheral tissues, such as the liver, skeletal muscle and adipose tissue [22,23]. 
Another systemic factor influencing insulin sensitivity is adiponectin. Plasma adiponectin levels in 
humans are negatively correlated with fasting insulin concentrations and positively correlated with 
insulin sensitivity, suggesting that the hormone is able to sensitize peripheral tissues to insulin action. 
However, certain inflammatory mediators, such as TNF-a and IL-6, which have been shown to be 
elevated in obese and insulin resistant individuals, are inhibitors of adipose tissue adiponectin mRNA 
expression and protein secretion [24]. In addition, adiponectin impairs the production of proinflammatory 
cytokines, such as TNF-a and interferon-g (IFN-g), in human macrophages and reduces their phagocytic 
capacity while inducing the production of the anti-inflammatory mediators IL-10 and IL-1 receptor 
antagonist (IL-1RA) by human monocytes, monocyte-derived macrophages and dendritic cells [25]. 
3. Vitamin D and Inflammation 
During the exposure to sunlight, ultraviolet B (UVB) photons penetrate into the skin and are 
absorbed by 7-dehydrocholesterol inducing the formation of previtamin D (Figure 1). This is an 
unstable form of vitamin D that rapidly undergoes rearrangement to form vitamin D3 (cholecalciferol). 
Vitamin D2 (ergocalciferol) is the form of vitamin D that occurs in plants and is used to fortify certain 
foods, such as fluid milk. Both vitamin D forms eventually enter the circulation bound to a vitamin D 
binding protein and are metabolized in the liver by the vitamin D-25-hydroxylase enzyme (25-OHase Nutrients 2012, 4  55 
 
or CYP27A1) to 25-hydroxyvitamin D (calcidiol), the main vitamin D form circulating in plasma and 
a substrate for production of the hormonally active metabolite 1,25-dihydroxyvitamin D, 1,25(OH)2D3 
(calcitriol) [26]. 
Figure 1. Cutaneous synthesis and metabolism of vitamin D. In the skin,   
7-dehydrocholesterol (DHC) can be converted to pre-vitamin D in response to ultraviolet B 
(UVB) radiation from the sun. Pre-vitamin D is then converted to vitamin D. Continued 
cutaneous exposure to UVB can produce various photoproducts (not shown) from both 
pre-vitamin D and vitamin D. Vitamin D (and other vitamin D metabolites) are carried in 
the blood by a 50-kD vitamin D-binding protein (DBP). Vitamin D is converted in the liver 
by the P450 enzyme CYP27A1 to 25-hydroxyvitamin D (25OHD), which is the major 
form of vitamin D found in the blood. In the kidney, another P450 enzyme, CYP27B1, 
adds a hydroxyl group at the C-1 position of 25OHD to form the active vitamin D hormone 
1,25-dihydroxyvitamin D, or 1,25(OH)2D3. Both 25OHD and 1,25(OH)2D3 are hydroxylated 
at C-24 by CYP24, which initiates their inactivation and metabolic breakdown. Vitamin D 
receptor (VDR)-mediated gene expression in response to 1,25(OH)2D3 occurs in many 
different tissues, including classical vitamin D target organs such as intestine, bone, and 
kidney. The active vitamin D hormone can also stimulate very rapid changes at the plasma 
membrane that are mediated by a 1,25(OH)2D3 membrane-associated rapid response steroid 
hormone binding protein (MARRS). Adapted from Martini and Wood [26]. 
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It is recognized that VDR, the receptor of the steroid hormone 1,25(OH)2D3, is widely distributed in 
more than 38 tissues, where it clearly controls vital genes related to bone metabolism, oxidative 
damage, chronic diseases and inflammation [27]. 
VDR is constitutively expressed by macrophages and dendritic cells, which suggests that vitamin D 
plays an important role in the modulation of inflammatory response. The 1,25(OH)2D3 can be 
synthesized by both cell types, since they express the enzymes 25-hydroxylase and 1α-hydroxylase, 
which enables the production of 25OHD and 1,25(OH)2D3, respectively [28,29]. In macrophages and 
dendritic cells, the enzyme 1α-hydroxylase is predominantly regulated by inflammatory mediators, 
such as interferon (IFN)-γ and lipopolysaccharides (LPS) [30].  
Macrophages are cells with a large capacity for cytokine production, in particular TNF-α, which is 
one of the most important products released from these cells [31]. Transcriptional activation of the 
TNF-α gene in macrophages is largely dependent on the NF-κB-dependent transcriptional activation, 
which is a major regulator of immune, inflammatory and stress responses [32]. In LPS-stimulated 
murine macrophages, 1,25(OH)2D3 up-regulates the inhibitor of NF-κB (IκB-α) by increasing mRNA 
stability and decreasing IkB-α phosphorylation. The increase in IκB-α levels leads to a reduction in 
nuclear translocation of NF-κB, thereby causing a decline in activity. In view of the key role of NF-κB 
as transcription factor of inflammatory mediators, it should be suggested that 1,25(OH)2D3 has   
anti-inflammatory action in macrophages [33]. Furthermore, 1,25(OH)2D3 suppresses the expression of 
TLR2 and TLR4 protein and mRNA in human monocytes in a time- and dose-dependent fashion 
(Figure 2) [34]. Incubation of isolated monocytes with 1,25(OH)2D3 attenuates the expression of 
proinflammatory cytokines involved in insulin resistance such as IL-1, IL-6 and TNF-alpha in type 2 
diabetic patients [35]. This fact may be related to the downregulation of NF-κB activity, as suggested 
by studies with P388D1 cells, a murine macrophage-like cell line [33,36]. 
Figure 2. Vitamin D modulates the inflammatory response of immune cells, such as 
macrophages and monocytes. Adapted from Borges et al. [37] (IKK: IκB kinase;   
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Despite the fact that experimental data support the involvement of vitamin D in modulating the 
inflammatory response, clinical and epidemiological studies are still scarce. Observational studies have 
generated conflicting results. Some cross-sectional studies indicate that hypovitaminosis D is 
associated with higher serum levels of inflammatory biomarkers, such as IL-6, TNF-α, and C-reactive 
protein (CRP), in healthy [38–41] and in obese subjects [42], while others could not confirm these 
findings [43–46]. Given the observational design, cross-sectional studies cannot prove causality or 
fully discount residual confounding by unmeasured variations. In this context, randomized placebo-controlled 
clinical trials are extremely useful to address the hypothesis that hypovitaminosis D might induce a 
higher inflammatory response. Table 1 presents clinical trials investigating the effect of vitamin D 
supplementation on serum inflammatory biomarkers. In some diseases associated with inflammation, 
such as chronic heart failure, chronic kidney disease and osteoporosis, vitamin D supplementation 
seems to attenuate serum TNF-α levels and to increase serum IL-10 concentration [47–49]. In a study 
involving subjects with either normal or impaired fasting glucose, the combined calcium-vitamin D 
supplementation (500 mg calcium + 700 IU cholecalciferol per day) for 3 years did not influence 
systemic CRP or IL-6 [50]. On the other hand, healthy overweight subjects participating in a   
weight-reduction program, when supplemented with vitamin D (3332 IU cholecalciferol/day for 
twelve months), experienced a greater decrease in serum TNF-α levels, but not in IL-6 and CRP 
concentration, when compared to placebo group [51].  
Table 1. Clinical trials investigating the effect of vitamin D supplementation on serum 
inflammatory biomarkers. 
Ref. 
Number and characteristics 
of subjects 
Intervention and duration 
Vitamin D effect on 
inflammatory serum biomarkers 
[10]  81 South Asian women with 
insulin resistance.  
Median serum 25OHD at 
baseline: 21 nmol/L.  
100 μg of vitamin D3 or 
placebo for 6 months. 
No effect on C-reactive protein. 
[47]  123 patients with congestive 
heart failure.  
Mean serum 25OHD at the 
baseline: 36 nmol/L. 
Oral supplementation  
(50 μg/day vitamin D3 plus  
500 mg of calcium) for  
9 months. 
No differences in TNF-α and  
C-reactive protein. Significant 
increase in interleukin 10. 
[48]  34 haemodialysis patients. 
Mean serum 25OHD at 
baseline: not reported. 
Oral (0.5 μg/day; n = 18) or 
intravenous (1 μg 3× week;  
n = 16) calcitriol for 6 months. 
Oral calcitriol: No differences in  
TNF-α, interleukin 1 and 
interleukin 6; 
Intravenous calcitriol: significant 
decrease in TNF-α, interleukin 1 
and interleukin 6. 
[49]  70 post-menopausal women 
with osteoporosis.  
Mean serum 25OHD at 
baseline: not reported. 
0.5 μg/day of calcitriol and 
1,000 mg/day of calcium or 
placebo (only 1,000 mg/day of 
calcium) for 6 months. 
Significant decrease in decrease in 
TNF-α and interleukin 1.  
No differences in interleukin 6. 
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Table 1. Cont. 
[50]  222 non-obese subjects with 
normal fasting glucose and 
92 non-obese with impaired 
fasting glucose. Mean serum 
25OHD at baseline in both 
groups: 76 nmol/L. 
700 IU of vitamin D3 or placebos for 
3 years. 
No differences in C-reactive 
protein and interleukin 6. 
[51]   200 healthy overweight 
subjects. Mean serum 
25OHD at baseline: 
30 nmol/L. 
83 μg/day of vitamin D3 or placebo in 
a double-blind manner for 1 year 
while participation in a  
weight-reduction program. 
More pronounced decrease 
in TNF-α in vitamin D group 
than in placebo group.  
[52]   218 long-term inpatients. 
Mean serum 25OHD at 
baseline: 23 nmol/L. 
0, 400 or 1200 IU/day of vitamin D3 
for 6 months.  
No differences in C-reactive 
protein. 
[53]   125 haemodialysis patients. 
Mean serum 25OHD at 
baseline: 32 nmol/L. 
100,000 IU/month of vitamin D3 for 
15 months. 
No differences in C-reactive 
protein. 
[54]   158 haemodialysis patients. 
Thirty-nine had diabetes and 
54 had hypertension.  
Mean serum 25OHD at 
baseline: 55.75 nmol/L. 
Vitamin D3 for 6 months according to 
25OHD serum levels at the baseline: 
- 50,000 IU/week for those with 
25OHD serum levels < 15 ng/mL; 
- 10,000 IU/week for those with 
25OHD between 16 and 30 ng/mL; 
- 2,700 IU 3x week for those with 
25OHD > 30 ng/mL. 
Significant decrease in  
C-reactive protein. 
[55]   30 haemodialysis patients. 
Mean serum 25OHD at 
baseline: 45.5 nmol/L. 
Weekly supplementation of vitamin D3 
for 24 weeks: 50,000 IU in the first 
12 weeks and 20,000 IU in the last 
12 weeks. 
Significant decrease in  
C-reactive protein and 
interleukin 6. 
4. Vitamin D and Type 2 Diabetes 
In contrast to type 1 diabetes, which is related to autoimmune destruction of pancreatic β cells, 
leading to absolute insulin deficiency, type 2 diabetes development involves impaired pancreatic β cell 
function, insulin resistance and inflammation. Although mechanistically unclear, it has been suggested 
that both environmental and genetic factors seem to be involved in type 2 diabetes development [56]; 
also, human and experimental data support the role of vitamin D on these pathways [8,57].  
Due to the presence of both 1-α-hydroxylase and VDR in pancreatic β cells, vitamin D is important 
for insulin synthesis and release [8,56]. In rats, vitamin D deficiency induced impairment of insulin 
secretion and glucose tolerance that was partially corrected after vitamin D replenishment [58,59]. 
Moreover, vitamin D is also involved in insulin sensitivity by controlling calcium flux through the 
membrane in both β cells and peripheral insulin-target tissues [57].  
The initial observations linking vitamin D to type 2 diabetes in humans came from studies showing 
that both healthy and diabetic subjects had a seasonal variation of glycemic control [60,61]. Since then, 
several recent human studies have associated vitamin D status with type 2 diabetes development Nutrients 2012, 4  59 
 
(Table 2). It should be highlighted that after statistical adjustments for potential risk factors of type 2 
diabetes, such as body mass index, the association between vitamin D and type 2 diabetes was attenuated 
in one study [62] and no longer significant in another one [63]. Almost all studies used serum 25OHD 
as a biomarker for vitamin D stores, while studies investigating vitamin D intake are scarce. 
Table 2. Human studies that associate vitamin D with type 2 diabetes. 
Ref.  Study design  Subjects included  Main outcome 
[62] Cohort  (Mini-Finland 
Health Survey) 
4097 individuals followed-up 
for 17 years. 
The highest versus the lowest serum 25OHD: 
RR = 0.70; 95% CI = 0.42–1.16);  
p for trend = 0.07).  
[63] Cohort  (Tromsø 
Study) 
4157 non-smokers and 
1962 smokers followed-up 
for 11 years. 
Baseline serum 25OHD was inversely 
associated with type 2 diabetes. 
[64] Cohort  (Nurses’ 
Health Study) 
83,779 women followed-up 
for 20 years. 
The highest versus the lowest category of 
vitamin D intake from supplements:  
RR = 0.87; 95% CI = 0.75–1.00;  
p for trend = 0.004). 
[65] Nested  case-control  412  cases and 986 controls.  The highest versus the lowest quartiles of 
serum 25OHD: OR = 0.28  
(95% CI = 0.10–0.81) in men and  
OR = 1.14 (95% CI = 0.60–2.17) in women. 
[66]  Meta-analysis  Polled data from 2 cohorts 
studies with 8627 individuals 
aged 40–79 years. 
The highest versus the lowest serum 25OHD: 
RR = 0.66; 95% CI = 0.50–0.87. 
[67] Cohort  (Framingham 
Study) 
3066 (1402 men and 
1664 women) followed-up 
for 7 years. 
A higher 25OHD serum levels is associated 
with decreased risk of type 2 diabetes.  
[6]  Nested case-control  608 cases and 559 controls.  The highest versus the lowest serum 25OHD 
quartile: OR = 0.52; 95% CI = 0.33–0.83. 
[68]  Cross-sectional  210 individual aged more  
than 40. 
Vitamin D deficiency was more common in 
diabetic compared to control. 
[69]  Cross-sectional  668 individuals aged  
70–74 years. 
Serum 25OHD < 50 nmol/L doubled the risk 
of newly diagnosed type 2 diabetes. 
[70] Cohort  (AusDiab 
study) 
5200 individuals; mean age 
51 years. 
Each 25 nmol/L increment in serum 25OHD 
was associated with a 24% reduced risk of 
type 2 diabetes (OR = 0.76;  
95% CI = 0.63–0.92). 
[71]  Cross-sectional  2465 subjects.  Serum 25OHD ≥ 80 nmol/L versus 
≤37 nmol/L in Caucasians: OR = 0.5;  
95% CI = 0.1–0.7. 
[9]  Systematic review of 
7 observational 
cohort studies. 
238,424 individuals aged  
30–75 years. 
Vitamin D intake >500 versus <200 UI:  
risk of type 2 diabetes 13% lower. Serum 
25OHD level (>25 ng/mL versus <14 ng/mL): 
risk of type 2 diabetes 43% lower.  
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Based on data from epidemiological studies, vitamin D supplementation is considered a potential 
and inexpensive therapy not only to decrease the risk, but also to improve glycemic parameters in 
type  2 diabetic patients [56]. In subjects at high risk of type 2 diabetes and with baseline serum 
25OHD level of 26.5 nmol/L, vitamin D supplementation (2000 UI once daily) was associated with 
improved β cell function in adults [72]. Daily intake of vitamin D-fortified yogurt (either with or 
without added calcium) improved serum 25OHD levels and glycemic status in type 2 diabetic patients 
with baseline 25OHD serum level of 44.5 nmol/L. In the same study, an inverse correlation between 
changes in serum 25OHD and fasting serum glucose and homeostasis model assessment of insulin 
resistance (HOMA-IR) was observed [73]. In a randomized, controlled, double-blinded intervention 
study, insulin resistant and vitamin D deficient (serum 25OHD < 50 nmol/L) subjects supplemented 
with vitamin D (4000 UI, daily, for 6 months) had improved serum 25OHD level, insulin sensitivity 
and insulin resistance when compared to controls, while no effects were observed on lipid profile,  
C-reactive protein and insulin secretion [10]. Similarly, in another randomized controlled trial, type 2 
diabetes patients with baseline serum 25OHD concentration <50 nmol/L treated with a single dose of 
vitamin D (100,000 or 200,000 UI) had lower systolic blood pressure than controls, but HOMA-IR 
was significantly improved only in subjects who received the highest dose [74].  
It is important to notice that in a meta-analysis by Pittas et al. [75], among six intervention trials 
reviewed (five with vitamin D alone and one with calcium and vitamin D), none were able to elicit a 
remarkable change in measures of glucose intolerance. In 2010, the same group of investigators 
revisited the question of vitamin D supplementation and plasma glucose [76]. From the randomized 
controlled trials included, three of them used vitamin D alone, and again no convincing evidence that 
vitamin D supplementation have benefits on blood glucose control was observed. However, not all 
studies reported 25OHD at the baseline and studies vary in the amount of vitamin D, type of vitamin D, 
length of supplementation, number of subjects, and subject characteristics such as non-diabetic, 
diabetics, healthy, overweight, insulin resistant, and gender. Thus, it would be important that all future 
trials describe 25OHD serum levels at the baseline and investigate not only blood glucose but also the 
role of vitamin D on glucose tolerance, insulin secretion, insulin sensitivity and ultimately with 
incident of type 2 diabetes. In order to provide more robust evidences on vitamin D in both prevention 
and management of type 2 diabetes, future trials should also investigate the role of higher doses of 
vitamin D supplementation in larger populations and for longer periods.  
Despite the lack of consensus regarding the adequate 25OHD serum levels to prevent and improve 
glycemic parameters in type 2 diabetes patients, it should be highlighted that the positive effect of 
vitamin D supplementation was observed when baseline 25OHD serum levels improved to near   
80 nmol/L after the intervention [10,73,74]. Accordingly, data from a cross-section study described 
that subjects who had 25OHD serum levels ≥80 nmol/L had decreased risk of developing type 2 
diabetes when compared to the ones who had ≤37 nmol/L [71].  
Although not uniformly, it was suggested that several genetic polymorphisms in genes related to 
vitamin D metabolism, such as DBP and VDR, may predispose subjects to type 2 diabetes [56]. Three 
variants of DBP gene (Gc1f, Gc1s, and Gc2) were associated with differences in oral glucose tolerance 
in nondiabetic Pima Indians [77]. Although no difference was observed between DBP genotypes 
regarding plasma glucose concentration, normal glucose tolerance Japanese subjects with Gc1s-2 and 
1s-1s genotypes had significantly higher fasting plasma insulin concentration and HOMA-IR than the Nutrients 2012, 4  61 
 
ones with 1f-1f [78]. However, DBP gene polymorphism was not associated with diabetes in while 
Americans of European origin [79] and in French Caucasians [80].  
A similar scenario is observed for VDR genotype. Regarding VDR ApaI polymorphisms, older 
adults without diabetes that have aa genotype had higher fasting plasma glucose and prevalence of 
glucose intolerance than those with AA genotype. In the same study, bb genotype of VDR BsmI 
polymorphism was associated with insulin resistance in subjects with diabetes [81]. VDR polymorphisms 
were also associated with type 2 diabetes in two Indian case-control studies [82,83]. However, in 
Polish [84] and Turkish [85] case-control studies, no differences were observed between groups 
regarding allele frequency of VDR polymorphisms. 
5. Conclusion 
In summary, there is consistent evidence supporting that vitamin D status is related to and is 
important to regulate some pathways related to type 2 diabetes development. Although experimental 
studies support the involvement of vitamin D in modulating the inflammatory response, human studies 
investigating inflammatory biomarkers specifically in subjects with or at high risk of developing type 2 
diabetes are scarce. Thus, based on available clinical and epidemiological data, the positive effects of 
vitamin D seem to be primarily related to its action on insulin secretion and sensitivity and secondary 
to its action on inflammation. Future studies specifically designed to investigate the role of vitamin D 
on type 2 diabetes using inflammation as the main outcome are urgently needed in order to provide a 
more robust link between vitamin D, inflammation and type 2 diabetes. Furthermore, genetic 
polymorphisms studies are also important in order to identify groups that are more susceptible to 
vitamin D deficiency and to developing type 2 diabetes in the population.  
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